On September 17, 10x Genomics, Inc. rose 5.57% in regular trading, reaching $76.2 per share, with turnover of $16.63 million. The stock has been in a strong uptrend amid a cluster of recent positive developments.
On the news front, the company recently announced a strategic partnership with medical AI firm Lunit to integrate its AI-powered pathology platform, Lunit SCOPE IO, into 10x Genomics' oncology biomarker discovery workflow. The collaboration aims to combine spatial molecular data with AI-driven pathology analysis, advancing tumor microenvironment characterization and accelerating clinically relevant biomarker discovery. This marks a key step in moving AI pathology from morphological analysis toward multi-omics integration.
Additionally, analyst sentiment has turned increasingly favorable. UBS recently raised its price target on the stock to $68 from $20, while RBC Capital Markets initiated coverage with a $70 target. The company also reported Q2 results that beat consensus estimates, with EPS of -$0.14 versus an expected -$0.24 loss, and raised full-year revenue guidance to $610M-$630M.
Within the Life Sciences Tools & Services sector, Tempus AI rose 9.04%, Illumina gained 3.54%, Thermo Fisher Scientific added 0.9%, while Danaher slipped 0.29%.
(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)
Comments